成大生物：公司流感病毒裂解疫苗(高剂量)获得药物临床试验批准通知书

Group 1 - The core point of the article is that Chengda Biologics (688739.SH) announced the approval of a clinical trial for a high-dose influenza virus split vaccine aimed at elderly individuals aged 60 and above, as well as high-risk groups with weakened immune systems [1] - The vaccine is expected to fill a gap in the domestic market for influenza prevention among vulnerable populations [1] - The company acknowledges that the development and commercialization process for the vaccine is lengthy, with uncertainties surrounding the clinical trial progress and product launch timeline [1]